Top 5 GSB Alumni Innovators in Healthcare 2021
Tom Lee, MD - CEO of Galileo
Tom is the CEO and visionary behind Galileo -- a next-generation health care delivery model designed for the future. Using innovative technology and human-centered design, Galileo improves clinical outcomes while reducing total cost of care across broad, complex and diverse populations.
Prior to Galileo, Tom helped build One Medical into the leading, independent primary care system in the country. In addition, he was responsible for mobile and web products at Epocrates, serving as Chief Medical Officer and lead designer.
Tom is a board-certified internist who completed training at Harvard’s Brigham and Women’s Hospital. He received his BS from Yale University, MD from the University of Washington School of Medicine, and MBA from Stanford University’s Graduate School of Business.
Naomi Allen - CEO of Brightline
Naomi Allen is the co-founder and CEO of Brightline, the leader in technology-enabled pediatric behavioral health care. As the mom of three amazing kids, Naomi has seen firsthand the challenges in navigating the behavioral health system. She started Brightline in 2019 to reinvent the way behavioral health care is delivered for children, teens, and their families. Today, Brightline is delivering integrated care through innovative technology, virtual behavioral health services, and a collaborative care team focused on supporting families across a range of common challenges.
Naomi is a leading entrepreneur with over 20 years of hands-on experience developing high-growth healthcare technology companies. Prior to starting Brightline, she was the Chief Growth Officer for Livongo, overseeing key strategic growth initiatives including new markets and acquisition operations, new category launch, and IPO preparation. She has held executive roles spanning operations, sales, and product as a founding team member of Castlight Health from inception to IPO. Before that, Naomi was a leader at McKinsey’s Silicon Valley office, helping to build their West Coast healthcare technology practice. She holds an MBA from Stanford Graduate School of Business and received her undergraduate degree at UNC-Chapel Hill.
Vidya Vasu-Devan - Director of the Strategic Investment Fund at Bill & Melinda Gates Foundation
Vidya leads the Gates Foundation’s $2.5bn Strategic Investment Fund (SIF) and chairs the SIF Investment Committee. Since 2012, Vidya has worked across sectors and geographies to source, structure, and manage venture capital, debt, and guarantee investments. SIF supports companies that have a critical role to play in achieving the foundation’s ambitious goals in global health and poverty alleviation and U.S. education and economic mobility. Vidya leads SIF’s investment efforts in the vaccines/biologics sector and has led and worked on investments in Achaogen (AKAO), AgBiome, Arsanis (ASNS), Biological E, BioNTech (BNTX), Charter School Growth Fund, Civic Builders, Curevac (CVAC), Just Biotherapeutics (acq. by Evotec), M-KOPA, Merck, and Sanofi.
Prior to joining the foundation, Vidya was an investment professional in the public markets proprietary hedge fund of Goldman Sachs (GSPS) where she led the healthcare portfolio and also invested in financial institutions. Prior to that, Vidya worked in investment banking at Goldman Sachs, advising and executing on innovative structured finance transactions for financial institution clients.
Vidya received an MBA and a certificate in Public Management and Social Innovation from the Stanford Graduate School of Business. She also holds a BA in Astrophysics with concentrations in Mathematics and Economics from Columbia University.
Bruce Cozadd, CEO and Co-founder of Jazz Pharmaceuticals
Mr. Cozadd co-founded Jazz Pharmaceuticals, Inc. in 2003 and has served as Chairman and Chief Executive Officer since April 2009. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd serves on the board of Biotechnology Innovation Organization (BIO), a biotechnology trade association, where he serves on its Health Section Governing Board. Mr. Cozadd also serves on the boards of two non-profit organizations, The Nueva School and SFJAZZ. He received a B.S. from Yale University with a double major in molecular biophysics and biochemistry and economics and an M.B.A from the Stanford Graduate School of Business.
Ann Lee-Karlon, PhD - Senior VP of Portfolio Management and Operations at Genentech
Ann Lee-Karlon is senior vice president and head of Portfolio Management and Operations for Genentech Research and Early Development. Leaders in her group oversee more than 30 drug development teams across oncology, immunology, ophthalmology, infectious diseases, and neuroscience.
Ann holds a BS in bioengineering from UC Berkeley, MBA from Stanford University, and PhD in bioengineering from UC San Diego, where she was a National Science Foundation Fellow. She completed a postdoctoral fellowship at University College London as an NSF International Research Fellow.
She served as president and board chair for the Genentech Patient Foundation (2016-2019), providing medicines to uninsured and underinsured patients. Ann was elected president and board chair for the Association of Women in Science (2014-2016), based in Washington, D.C. She was honored by the UC President's Office as one of the Remarkable Women of the University of California.
Ann is a board member for Eko Health, a startup focused on AI-driven software, advanced stethoscopes, and telemedicine for cardiopulmonary medicine. She is a Fellow of the Aspen Institute and a Fellow of the American Institute for Medical and Biological Engineering.